News Releases

December 21, 1999

Sekisui and Dainippon Form Alliance in an Anti-Atopic Dermatitis

Sekisui Chemical Co., Ltd. (hSekisuih, President: Naotake Okubo) and Dainippon Pharmaceutical Co., Ltd (hDainipponh, President: Kenjiro Miyatake) jointly announced that they have signed a license agreement in which Dainippon will exclusively receive the worldwide development and marketing rights of Sekisuif s series of ointment containing high concentration tocopherol acetate (vitamin E acetate), including their SEK-3001 ointment which is under development for the indication of skin diseases such as atopic dermatitis.

Sekisui found that ointment containing more than 10% of tocopherol acetate suppresses epidermic cell damage, and shows anti-inflammatory and moisturizing actions in animal models of skin diseases. Furthermore, the ointment shows low skin irritation in human patch tests.

Based on the above knowledge, Dainippon plans to develop this ointment as an agent for the treatment of dry skin dermatosis and contact dermatosis, such as atopic dermatitis, which are induced or worsened by epidermal cell damage.

The number of patients with dry skin dermatosis such as atopic dermatitis has shown a tendency to increase recently, and atopic dermatitis is now very common world-wide. For the treatment of atopic dermatitis, the following points are thought to be equally important:

1. Analysis and removal of causal and aggravating factors
2. Normalization of skin function (skin care)
3. Medication

Regarding medication, topical steroids, antihistamines and antiallergic agents have been recommended for the treatment of atopic dermatitis. However, safer agents targeting the normalization of skin function are now being researched.

We believe that these ointments, including SEK-3001 ointment, will greatly contribute to the treatment of dry skin dermatosis and contact dermatosis, because they are a new type of drug targeting epidermal cell function, and are safe and highly effective.

Upon this agreement, Dainippon plans to continue the development of Sekisuifs SEK-3001 ointment.